Galena Biopharma, Inc. (GALE) Shares Bought by Virtu KCG Holdings LLC

Virtu KCG Holdings LLC increased its holdings in shares of Galena Biopharma, Inc. (NASDAQ:GALE) by 677.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 224,050 shares of the biotechnology company’s stock after buying an additional 195,230 shares during the quarter. Virtu KCG Holdings LLC owned 0.60% of Galena Biopharma worth $130,000 as of its most recent SEC filing.

Separately, Renaissance Technologies LLC acquired a new stake in Galena Biopharma during the 1st quarter worth $976,000. 20.53% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Galena Biopharma, Inc. (GALE) Shares Bought by Virtu KCG Holdings LLC” was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this news story on another publication, it was copied illegally and republished in violation of international trademark & copyright legislation. The legal version of this news story can be viewed at

Galena Biopharma (NASDAQ:GALE) last issued its quarterly earnings results on Monday, August 14th. The biotechnology company reported ($0.16) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.01). During the same quarter last year, the company earned $0.05 EPS.

Separately, Maxim Group reaffirmed a “hold” rating on shares of Galena Biopharma in a research note on Wednesday, August 9th.

About Galena Biopharma

Galena Biopharma, Inc is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302.

Receive News & Ratings for Galena Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galena Biopharma Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply